<DOC>
	<DOCNO>NCT01444469</DOCNO>
	<brief_summary>Acute attack ( exacerbation ) asthma common cause great deal suffer asthmatic patient . Current treatment asthma attack completely effective new good treatment need . Viruses often cause asthma attack bacterial lung infection also associate asthma attack . However , role bacteria uncertain . Current asthma guideline doctor treat asthma exacerbation recommend routine use antibiotic . The investigator would like investigate whether azithromycin , safe well tolerate antibiotic ( antibacterial ) use many year treatment respiratory disease , might benefit asthma attack . As evidence azithromycin anti-viral property may add benefit ( antibiotic n't usually affect virus ) . By look effect azithromycin asthma attack help u show whether azithromycin recommend acute asthma attack addition usual care provide patient may help recover quick exacerbation . The investigator also able look azithromycin may effective - anti-bacterial and/or anti-viral effect .</brief_summary>
	<brief_title>AZithromycin Against pLacebo Exacerbations Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Azithromycin</mesh_term>
	<criteria>Inclusion criterion Patients meet follow criterion consider admission study : Adults , either sex , age 1855 year age 56 65 &lt; 20 pack year smoke history &gt; 65 &lt; 5 pack year smoke history Patients document history asthma &gt; 6 consecutive month , Patients present within 48 hour ( initial presentation medical care ) acute deterioration asthma control ( increase wheeze , dyspnea and/or cough and/or reduce PEF ) require course oral steroid Patients PEF FEV1 le 80 % predict normal patient 's best presentation , recruitment time elapse presentation recruitment Patients must able complete diary quality life questionnaire . Patients must sign date inform consent prior study procedure . Exclusion criteria Patients present follow include study : Patients know prolongation QT interval , history torsades de pointes , congenital long QT syndrome , bradyarrhythmias uncompensated heart failure , patient drug know prolong QT interval patient ongoing proarrhythmic condition uncorrected hypokalemia hypomagnesemia , clinically significant bradycardia , patient receive Class IA ( quinidine , procainamide ) Class III ( dofetilide , aminodarone , sotalol ) antiarrhythmic agent . Smokers age 5665 &gt; 20 pack year history , age &gt; 65 &gt; 5 pack year history Patients require immediate placement ICU Patients use oral systemic antibiotic within 28 day prior enrolment Patients know impaired hepatic function ( ALT/AST &gt; 2 ULN ) Patients significant lung disease ( include COPD ) asthma Patients &gt; 20mg oral corticosteroid maintenance therapy Patients require antibiotic therapy Patients receive medication disease condition infection could interfere evaluation drug efficacy safety Women breastfeed pregnant , demonstrated urine pregnancy test carry exposure study medication start study procedure could pose risk foetus Patients suspect known hypersensitivity , suspect serious adverse reaction Azithromycin macrolide ketolide class antibiotic , erythromycin excipients thereof Patients receive treatment investigational drug within 1 month prior study entry , treatment plan study period treatment follow phase Patients concomitant condition ( include clinically relevant cardiovascular , hepatic , neurologic , endocrine , major systemic disease ) make implementation protocol interpretation study result difficult Patients mental condition render unable understand nature , scope , possible consequence study . Patients unlikely comply protocol , e.g. , uncooperative attitude , inability return followup visit . No subject allow enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Asthma exacerbation</keyword>
	<keyword>Respiratory disease</keyword>
	<keyword>Viral infection</keyword>
	<keyword>Macrolide/ketolide antibiotic</keyword>
	<keyword>Mycoplasma pneumoniae ( M. pneumoniae )</keyword>
	<keyword>Chlamydophila pneumoniae ( C. pneumoniae )</keyword>
</DOC>